8-K 1 v398491_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

January 12, 2015

LIPOCINE INC.

(Exact name of registrant as specified in its charter)

Commission File No. 001-36357

| Delaware |  | 99-0370688 |
| (State or other jurisdiction of incorporation) |  | (IRS Employer Identification Number) |

675 Arapeen Drive, Suite 202

Salt Lake City, Utah 84108

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (801) 994-7383

Former name or former address, if changed since last report: Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

| Item 7.01 | Regulation FD Disclosures

On January 12, 2015, Lipocine Inc. issued a press release to report the Phase 1b clinical study results with LPCN 1107. The press release is filed as Exhibit 99.1 and is incorporated herein by reference.

The Company is planning to attend the J.P. Morgan Annual Healthcare Conference to be held January 12-15, 2015. During the conference, the Company will be meeting with investors and presenting materials to the investors regarding the Company. The Company’s materials to be used in the presentations are attached hereto as Exhibit 99.2.

| Item 9.01 | Financial Statements and Exhibits.

| (d) | Exhibits

The following exhibits are filed with this report:

Exhibit No. |  | Description
99.1 |  | Press Release Announces Phase 1b Results with LPCN 1107
99.2 |  | Corporate Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

|  |  | LIPOCINE INC.
Date: | January 12, 2015 |  | By: | /s/ Mahesh V. Patel
|  |  |  | Mahesh V. Patel
|  |  |  | President and Chief Executive Officer